ClinicalTrials.gg
CompletedNCT01302392FOCUSUpdated May 2, 2017Results posted

A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma

A Phase 3 interventional study of Carfilzomib and Best Supportive Care in Multiple Myeloma, sponsored by Amgen. Completed at 68 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-02.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
315
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
11th of 113
315 · median 54
Started
2010
with 2 others
Phase 3
15 of 113
1 open now
Registered
12th of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 11th largest by enrollment, is one of 3 that started in 2010, is one of 15 in phase 3, and was the 12th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, open-label, multicenter study comparing two treatment regimens for subjects with multiple myeloma who have received all available approved treatment options and may therefore be considered candidates for palliative care.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Multiple myeloma
  2. based on central laboratory values, as defined by one or both of the following criteria (assessed within 21 days prior to randomization):

    • Serum M-protein

      • Serum protein electrophoresis (SPEP): ≥ 0.5 g/dL
      • For immunoglobulin A (IgA) patients whose disease can only be reliably measured by serum quantitative immunoglobulin (qIgA): > 750 mg/dL (0.75 g/dL)
    • Urine Bence Jones protein: ≥ 200 mg/24 h
  3. Responsive (defined as a 25% or greater decrease in M-protein or total protein) to at least one
  4. multiple myeloma, defined as disease progression while on or after at least 1 prior treatment regimen
  5. Refractory multiple myeloma, defined as meeting one or more of the following:

    • Nonresponsive to most recent therapy (eg, stable disease only, or progressive disease while on treatment)
    • Disease progression within 60 days of discontinuation from most recent therapy
  6. Received 3 or more prior therapeutic regimens for multiple myeloma
  7. Adequate prior treatment with bortezomib (if less than 4 complete cycles, the reason for discontinuation must be reviewed by the Medical Monitor and the reason documented)
  8. Prior treatment with an immunomodulatory agent (lenalidomide, if available, and/or thalidomide)
  9. Prior treatment with an alkylating agent (standard or high-dose)
  10. Prior treatment with a
  11. Criterion no longer applicable (with Amendment 2, Criterion 11, the requirement of "prior treatment with an anthracycline unless not clinically indicated" is removed.)
  12. Age ≥ 18 years
  13. of at least 1 month
  14. (ECOG) performance status 0-2
  15. Adequate hepatic function, with serum (ALT) \< 4 times the and serum \< 2.5 mg/dL (42.5 µmol/L). Patients with total bilirubin ≥ 2.5 mg/dL may enrol if their serum direct bilirubin is \< 2.5 mg/dL.
  16. Total white blood cell (WBC) count ≥ 1.5 × 10\^9/L and (ANC) ≥ 1.0 × 10\^9/L (use of colony-stimulating factors to achieve these counts is allowed)
  17. ≥ 7.5 g/dL (75 g/L)

    -Use of erythropoietic stimulating factors is allowed:

    • For all patients who receive a red blood cell (RBC) transfusion within 28 days of obtaining the Screening hemoglobin value. The following information must be provided for the Medical Monitor's review for assessment for eligibility:

      • Pre-transfusion hemoglobin (Hb)
      • Number of RBC units administered
      • Use of erythropoietic stimulating factors
  18. count ≥ 30 × 10\^9/L

    -There is no restriction on platelet transfusions or thrombopoietic growth factor before or during the screening period

    • For all patients who receive a platelet transfusion within 7 days of obtaining the Screening platelet value, the following information must be provided for the Medical Monitor's review for assessment of eligibility

      • Pre-transfusion platelet count
      • Number of platelet units administered
      • Use of thrombopoietic growth factors
  19. (CrCl) ≥ 15 mL/minute (either measured or calculated using a standard formula such as Cockcroft and Gault) and dialysis-independent
  20. Written in accordance with regulatory guidelines
  21. Female patients of must have a negative serum or urine pregnancy test within 7 days of the first dose of study treatment and agree to use an effective method of during the study and for 3 months following the last dose of study treatment. females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from these requirements. Male patients must use an effective barrier method of contraception during the study and for 3 months following the last dose if sexually active with a female of childbearing potential.

Exclusion criteria

Exclusion Criteria:

  1. Waldenström's macroglobulinemia or IgM myeloma
  2. to all prior therapies
  3. Disease measurable only by serum free light chain assay (SFLC)
  4. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  5. Plasma cell leukemia (> 2.0 × 10\^9/L circulating plasma cells by standard differential)
  6. Prior carfilzomib treatment
  7. Chemotherapy (approved or ) within 14 days prior to randomization
  8. Immunotherapy or antibody therapy within 28 days prior to randomization
  9. therapy at a dose equivalent to dexamethasone > 4 mg/day within 14 days prior to randomization
  10. Radiotherapy within 7 days prior to randomization
  11. Major surgery within 21 days prior to randomization
  12. Congestive heart failure ( Class III or IV) or symptomatic cardiac ischemia, conduction system abnormalities uncontrolled by conventional intervention (conduction abnormalities not clinically warranting intervention are allowed)
  13. Myocardial infarction in the previous 3 months
  14. Acute active infection requiring systemic treatment (antibiotics, antivirals, or antifungals) within 14 days prior to randomization
  15. Known seropositivity
  16. Active hepatitis A, B, or C infection
  17. Other within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix, vulva, or breast; c) prostate cancer of Gleason Score 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder, carcinoma in situ of the breast, or benign tumors of the adrenal or pancreas
  18. Significant neuropathy (Grades 3-4, or Grade 2 with pain) at the time of randomization
  19. Any other medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a patient's ability to give
  20. Pregnant or lactating females
  21. to any of the required concomitant drugs or supportive treatments, including or known history of allergy to carfilzomib, Captisol® (a cyclodextrin derivative used to solubilize carfilzomib) all anticoagulation and antiplatelet options, antiviral drugs; or intolerance to hydration due to preexisting pulmonary or cardiac impairment
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
315 participants (actual)

Study arms

  • Active comparator
    Best Supportive Care

    Drug: Best Supportive Care

  • Experimental
    Carfilzomib

    Drug: Carfilzomib

Interventions

  • 20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days \[Days 1, 2, 8, 9, 15, 16\] for individual subjects).

    Also known as: PR-171

  • DrugBest Supportive Care

    Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid). Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle).

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time elapsed between the randomization date and the date of death. Participants who were still alive were censored at date when the subject is last known alive or the data cutoff date, whichever occurs earlier.

    Time frame: From randomization through the final analysis data cutoff with longest follow-up time of approximately 45 months. Median follow up times were 27.8 months and 29.8 months for Carfilzomib and Best Supportive Care groups, respectively.

Secondary outcomes

  1. Progression-free Survival

    Kaplan-Meier estimate of median time from randomization to progressive disease (PD) or all-cause death. PD was assessed using International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). 1 or more conditions were required to meet PD: 2 consecutive rising serum or urine M-protein from central lab; documented new bone lesion(s) or soft tissue plasmacytoma(s) or increased size of existing bone lesion(s) or plasmacytoma(s); or confirmed hypercalcemia due solely to plasma cell proliferative disorder (local lab greater than 11.5 mg/dL on 2 separate occasions). Censoring conditions (censoring dates) were: no post-baseline disease assessment (DA) (randomization date); started non-protocol systemic anticancer treatment before PD or death (last DA date before such treatment); died or had PD after more than 1 missed DA (last DA date without PD before the first missed visit); or were alive and without documentation of PD, including lost to follow-up without PD (last DA date).

    Time frame: From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.

  2. Overall Response

    Number of participants who achieved confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as their best response. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC).

    Time frame: From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.

  3. Duration of Response

    Duration of response (DOR) was calculated for subjects who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). Duration of response was defined as the time in months from the initial start of response (PR or better) to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for progression-free survival.

    Time frame: From the time achieving response through the final analysis data cutoff with longest follow-up time of approximately 29 months.

  4. Clinical Benefit Response

    Number of participants who achieved confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), or minimal response (MR) as their best response. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC). (MR was determined using European Group for Blood and Marrow Transplantation criteria)

    Time frame: From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.

  5. Duration of Clinical Benefit

    Duration of Clinical Benefit was calculated for subjects who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR) or minimal response (MR). Duration of Clinical Benefit was defined as the time in months from the initial start of response (MR or better) to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for progression-free survival.

    Time frame: From time of achieving clinical benefit through the final analysis data cutoff with longest follow-up time of approximately 30 months.

  6. Disease Control

    Number of participants who achieved confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), or stable disease (SD) lasting ≥ 8 weeks as their best response. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC). (MR was determined using European Group for Blood and Marrow Transplantation criteria)

    Time frame: From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.

  7. Duration of Disease Control

    Duration of Disease Control was calculated for subjects who achieved disease control. Duration of Disease Control was defined as the time in months from randomization to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for progression-free survival.

    Time frame: From time of achieving disease control through the final analysis data cutoff with longest follow-up time of approximately 31 months.

07

Results

Posted Aug 4, 2015

Participant flow

Subjects were enrolled from 06 Sep 2010 to 21OCT2012. Results are reported as of the data cut-off date of 10 Jul 2014.

Participant flow — Overall Study
MilestoneBest Supportive CareCarfilzomib
Started158157
Treated153157
Completed151156
Not completed71
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject61

Outcome measures

PrimaryOverall Survival

Time elapsed between the randomization date and the date of death. Participants who were still alive were censored at date when the subject is last known alive or the data cutoff date, whichever occurs earlier.

Time frame:
From randomization through the final analysis data cutoff with longest follow-up time of approximately 45 months. Median follow up times were 27.8 months and 29.8 months for Carfilzomib and Best Supportive Care groups, respectively.
Reported as:
Median · months
Overall Survival
monthsBest Supportive CareCarfilzomib
Overall Survival10.0 (7.7 to 12.0)10.2 (8.4 to 14.4)
Statistical analysis
  • Best Supportive Care vs Carfilzomib · Log Rank · p = 0.4172 (Based on 1-sided test.) · Hazard ratio (hr): 0.975 · 95% CI 0.760 to 1.249Analysis was stratified by the number of previous therapies (3 vs 4 vs ≥ 5) and geographical region (Europe vs. non-Europe)
SecondaryProgression-free Survival

Kaplan-Meier estimate of median time from randomization to progressive disease (PD) or all-cause death. PD was assessed using International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). 1 or more conditions were required to meet PD: 2 consecutive rising serum or urine M-protein from central lab; documented new bone lesion(s) or soft tissue plasmacytoma(s) or increased size of existing bone lesion(s) or plasmacytoma(s); or confirmed hypercalcemia due solely to plasma cell proliferative disorder (local lab greater than 11.5 mg/dL on 2 separate occasions). Censoring conditions (censoring dates) were: no post-baseline disease assessment (DA) (randomization date); started non-protocol systemic anticancer treatment before PD or death (last DA date before such treatment); died or had PD after more than 1 missed DA (last DA date without PD before the first missed visit); or were alive and without documentation of PD, including lost to follow-up without PD (last DA date).

Time frame:
From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.
Reported as:
Median · months
Progression-free Survival
monthsBest Supportive CareCarfilzomib
Progression-free Survival3.3 (2.2 to 5.2)3.7 (2.8 to 4.2)
SecondaryOverall Response

Number of participants who achieved confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as their best response. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC).

Time frame:
From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.
Reported as:
Number · participants
Overall Response
participantsBest Supportive CareCarfilzomib
Overall Response1830
SecondaryDuration of Response

Duration of response (DOR) was calculated for subjects who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). Duration of response was defined as the time in months from the initial start of response (PR or better) to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for progression-free survival.

Time frame:
From the time achieving response through the final analysis data cutoff with longest follow-up time of approximately 29 months.
Reported as:
Median · months
Duration of Response
monthsBest Supportive CareCarfilzomib
Duration of Response9.5 (3.7 to NA)7.2 (4.6 to 12.0)
SecondaryClinical Benefit Response

Number of participants who achieved confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), or minimal response (MR) as their best response. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC). (MR was determined using European Group for Blood and Marrow Transplantation criteria)

Time frame:
From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.
Reported as:
Number · participants
Clinical Benefit Response
participantsBest Supportive CareCarfilzomib
Clinical Benefit Response3349
SecondaryDuration of Clinical Benefit

Duration of Clinical Benefit was calculated for subjects who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR) or minimal response (MR). Duration of Clinical Benefit was defined as the time in months from the initial start of response (MR or better) to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for progression-free survival.

Time frame:
From time of achieving clinical benefit through the final analysis data cutoff with longest follow-up time of approximately 30 months.
Reported as:
Median · months
Duration of Clinical Benefit
monthsBest Supportive CareCarfilzomib
Duration of Clinical Benefit8.3 (6.5 to 12.9)6.4 (4.9 to 8.3)
SecondaryDisease Control

Number of participants who achieved confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), or stable disease (SD) lasting ≥ 8 weeks as their best response. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC). (MR was determined using European Group for Blood and Marrow Transplantation criteria)

Time frame:
From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.
Reported as:
Number · participants
Disease Control
participantsBest Supportive CareCarfilzomib
Disease Control107119
SecondaryDuration of Disease Control

Duration of Disease Control was calculated for subjects who achieved disease control. Duration of Disease Control was defined as the time in months from randomization to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for progression-free survival.

Time frame:
From time of achieving disease control through the final analysis data cutoff with longest follow-up time of approximately 31 months.
Reported as:
Median · months
Duration of Disease Control
monthsBest Supportive CareCarfilzomib
Duration of Disease Control6.6 (5.4 to 8.8)5.5 (3.9 to 6.5)

Adverse events

Collected over From randomization through the final analysis data cutoff with range of follow-up time of 0.4 - 138.3 weeks with median of 10.7 weeks in Best Supportive Care arm, and 0.3 - 138.4 weeks with median of 16.3 weeks in carfilzomib arm. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Best Supportive Care—78/153 (51%)135/153 (88.2%)
Carfilzomib—92/157 (58.6%)141/157 (89.8%)
Most frequent serious events
Showing 10 of 120
Most frequent serious events
EventBest Supportive CareCarfilzomib
Disease progressionGeneral disorders19/15316/157
PneumoniaInfections and infestations18/15310/157
Renal failure acuteRenal and urinary disorders6/15315/157
AnaemiaBlood and lymphatic system disorders8/1534/157
HypercalcaemiaMetabolism and nutrition disorders4/1537/157
PyrexiaGeneral disorders2/1536/157
BronchopneumoniaInfections and infestations5/1536/157
Back painMusculoskeletal and connective tissue disorders3/1536/157
ThrombocytopeniaBlood and lymphatic system disorders5/1533/157
Respiratory tract infectionInfections and infestations4/1531/157
Most frequent other events
Showing 10 of 46
Most frequent other events
EventBest Supportive CareCarfilzomib
AnaemiaBlood and lymphatic system disorders72/15388/157
ThrombocytopeniaBlood and lymphatic system disorders43/15358/157
PyrexiaGeneral disorders28/15341/157
NauseaGastrointestinal disorders14/15331/157
FatigueGeneral disorders28/15329/157
AstheniaGeneral disorders20/15326/157
NeutropeniaBlood and lymphatic system disorders23/15322/157
DiarrhoeaGastrointestinal disorders18/15323/157
HypertensionVascular disorders9/15323/157
DyspnoeaRespiratory, thoracic and mediastinal disorders12/15321/157

Baseline characteristics

Age, Continuous
Age, Continuous(years)Best Supportive CareCarfilzomibTotal
Mean65.5 ± 8.0263.3 ± 10.7164.4 ± 9.50
Sex: Female, Male
Sex: Female, Male(Participants)Best Supportive CareCarfilzomibTotal
Female6275137
Male9682178
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Best Supportive CareCarfilzomibTotal
American Indian or Alaska Native000
Asian415
Native Hawaiian or Other Pacific Islander000
Black or African American112
White148151299
Other549
Region
Region(participants)Best Supportive CareCarfilzomibTotal
Europe138140278
Non-Europe201737
Number of Prior Regimens to Treat Multiple Myeloma
Number of Prior Regimens to Treat Multiple Myeloma(participants)Best Supportive CareCarfilzomibTotal
3191736
4353469
≥5104106210
08

Study locations

68 sites
  • Nedlands, Australia
  • Perth, Australia
  • Linz, Austria
  • Salzburg, Austria
  • Vienna, Austria
  • Arlon, Belgium
  • Brugge, Belgium
  • Brussels, Belgium
  • Roeselare, Belgium
  • Brno, Czechia
  • Hradec Kralov, Czechia
  • Olomouc, Czechia
  • Prague, Czechia
  • Lyon, France
  • Nantes, France
  • Nimes, France
  • Dresden, Germany
  • Giessen, Germany
  • Koblenz, Germany
  • Mainz, Germany
  • Muenchen, Germany
  • Ulm, Germany
  • Athens, Greece
  • Rio Patras, Greece
  • Budapest, Hungary
  • Debrecen, Hungary
  • Gyor, Hungary
  • Gyula, Hungary
  • Kaposvar, Hungary
  • Pecs, Hungary
  • Szeged, Hungary
  • Haifa, Israel
  • Jerusalem, Israel
  • Kfar Saba, Israel
  • Nahariva, Israel
  • Petah-Tikva, Israel
  • Sheba, Israel
  • Ancona, Italy
  • Novara, Italy
  • Roma, Italy
  • Torino, Italy
  • Incheon, Korea, Republic of
  • Seoul, Korea, Republic of
  • North Shore City, New Zealand
  • Gdansk, Poland
  • Lodz, Poland
  • Pila, Poland
  • Torum, Poland
  • Warsaw, Poland
  • Wroclaw, Poland
  • Zamosc, Poland
  • Moscow, Russian Federation
  • St. Petersburg, Russian Federation
  • Beograd, Serbia
  • Nis, Serbia
  • Bratislava, Slovakia
  • Barcelona, Spain
  • Guipuzcoa, Spain
  • Murcia, Spain
  • Salamanca, Spain
  • Sevilla, Spain
  • Valencia, Spain
  • Zaragoza, Spain
  • Uppsala, Sweden
  • Hampshire, United Kingdom
  • London, United Kingdom
  • Manchester, United Kingdom
  • Oxford, United Kingdom
09

References and documents

Publications

  • Hajek R, Masszi T, Petrucci MT, Palumbo A, Rosinol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, David M, de la Rubia J, Drach J, Gasztonyi Z, Gornik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan;31(1):107-114. doi: 10.1038/leu.2016.176. Epub 2016 Jun 24. PubMed 27416912 ↗
  • Hajek R, Bryce R, Ro S, Klencke B, Ludwig H. Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). BMC Cancer. 2012 Sep 19;12:415. doi: 10.1186/1471-2407-12-415. PubMed 22992303 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Jul 2014 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2011
First posted
Feb 24, 2011
Start
Sep 2010
Primary completionActual
Jul 2014
CompletionActual
Sep 2015
Results first posted
Aug 4, 2015
Last update
May 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01302392
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 24, 2011
Start date
Sep 2010
Primary completion
Jul 2014
Completion
Sep 2015
Results posted
Aug 4, 2015
Last update
May 2, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carfilzomib

Start the discussion